Pelcitoclax is under clinical development by Ascentage Pharma Group International and currently in Phase II for Sezary Syndrome. According to GlobalData, Phase II drugs for Sezary Syndrome have a 38% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Pelcitoclax’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pelcitoclax (APG-1252) is under development for the treatment of natural Killer/T-cell lymphoma (NK/TCL),relapsed/refractory peripheral T cell lymphomas (PTCL), relapsed or refractory non-Hodgkin lymphoma(NHL), angioimmunoblastic T-cell lymphoma, extranodal NK/T-cell lymphoma, ALK-positive anaplastic large cell lymphoma, ALK-negative anaplastic large cell lymphoma, sezary syndrome, metastatic non-small cell lung cancer, small cell lung cancer, solid tumors and brain metastasis, metastatic breast cancer, neuroendocrine tumors, HER2 positive gastric cancers, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer, and endometrial cancer. It is a new chemical entity. The drug candidate acts by targeting Bcl-2, Bcl-xL protein. It is administered through intravenous route and also intravenous drip. It was also under development for the treatment of lymphoma, metastatic liver cancer, colorectal cancer, myelofibrosis, post essential thrombocythemia/polycythemia vera.
Ascentage Pharma Group International overview
Ascentage Pharma Group International (Ascentage Pharma) is a biotechnology company that discovers and develops targeted small-molecule therapies for the treatment of cancer, hepatitis B and age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. The company product pipeline includes HQP8361, APG-2449, APG-2575, APG-1252, APG-115, APG-1387, APG-5918, APG-265, AS1266 and UBX1967/1325. Ascentage Pharma lead candidate HQP8361 is a second-generation c-Met kinase inhibitor for the treatment of c-Met positive cancers, gastric cancer, non-small cell lung cancer and liver cancer. It operates research and development centers and production facilities in Hong Kong, China, and the US. Ascentage Pharma is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Pelcitoclax’s drug-specific PTSR and LoA scores, buy the report here.